




RealRate

PHARMACEUTICAL 2021

Brooklyn ImmunoTherapeutics Inc.
Rank 348 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

Brooklyn ImmunoTherapeutics Inc. Rank 348 of 409



The relative strengths and weaknesses of Brooklyn ImmunoTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Brooklyn ImmunoTherapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 592% points. The greatest weakness of Brooklyn ImmunoTherapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 507% points.

The company's Economic Capital Ratio, given in the ranking table, is -513%, being 158% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	1,724
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,360
Liabilities, Non-Current	532
Other Assets	1,519
Other Compr. Net Income	-23
Other Expenses	4,012
Other Liabilities	2.0
Other Net Income	1,888
Property and Equipment	502
Research and Development	0
Revenues	5,800
Selling, General and Administrative Expense	8,091

Output Variable	Value in 1000 USD
Assets	3,745
Liabilities	2,894
Expenses	12,103
Stockholders Equity	851
Net Income	-4,415
Comprehensive Net Income	-4,426
Economic Capital Ratio	-513%

